

09-08-06

C25

Attorney's Docket No.: 18202-020001 / 1088



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lin Zhi et al.

Patent No.: 7,071,205

Issue Date: July 4, 2006

Serial No.: 10/684,229

Filed: October 10, 2003

Title: 5-CYCLOALKENYL 5H-CHROMENO[3,4-F]QUINOLINE DERIVATIVES  
AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR  
COMPOUNDS

Art Unit: 1625

Examiner: Charanjit Aulakh

Conf. No.: 8639

Cust. No.: 20985

**Attn: Certificate of Corrections Branch**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Dear Sir:

Transmitted herewith are a Request for a Certificate of Correction pursuant to C.F.R. § 1.322 & 1.323 (12 pages), Certificate of Correction Form PTO-1050 (11 pages), a copy of the examiner initialed Form PTO-1449 (1 page) delivered on July 1, 2005, and a return postcard for filing in connection with the above-identified application. One or more of the errors sought to be corrected were made by applicant, and a check for \$100 is enclosed to cover the required fee of 37 CFR §1.20(a).



The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie Seidman  
Reg. No. 33,719

*Certificate*

SEP 12 2006

*of Correction*

Attorney Docket No. 18202-020001 / 1088

Address all correspondence to:

Stephanie Seidman

Fish & Richardson P.C.

12390 El Camino Real

San Diego, California 92130

Telephone: (858) 678-4777

Faxsimile: (202) 626-7796

email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 740125918 US  
Date of Deposit September 6, 2006

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

SEP 13 2006



Attorney's Docket No.: 18202-020001 / 1088

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lin Zhi et al.  
Patent No. : 7,071,205  
Issue Date : July 4, 2006  
Serial No. : 10/684,229  
Filed : October 10, 2003  
Title : 5-CYCLOALKENYL 5H-CHROMENO[3,4-F]QUINOLINE DERIVATIVES AS  
SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS

Art Unit : 1625  
Examiner : Charanjit Aulakh  
Conf. No. : 8639  
Cust. No. : 20985

**Attn: Certificate of Corrections Branch**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.322 and 1.323, the patentee respectfully requests that a Certificate of Correction be issued for the above-referenced patent to correct the following errors:

**IN THE TITLE PAGES:**

In Item [56] References Cited, in U.S. PATENT DOCUMENTS:

please add the following reference: -6,001,846 A 12/1999 Edwards et al. 514/285-;  
in 6,566,358 please replace "Zhi et al." with -Zhang et al.-; and  
in 6,566,372 please replace "West et al." with -Zhi et al.-.

In Item [56] References Cited, in OTHER PUBLICATIONS:

in Hamann et al., please replace "dihyrd" with -dihydro-.

09/01/2006 09:02:20Z 60006001 7026500

USPTO GEN

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**  
"Express Mail" Mailing Label Number EV 740125918 US

Date of Deposit September 6, 2006

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman


**IN THE SPECIFICATION:**

At column 8, Table A, row R<sup>1</sup>, please replace “C<sub>1</sub>-C haloalkyl” with –C<sub>1</sub>-C<sub>4</sub> haloalkyl–; at column 9, Table A, row R<sup>9</sup>, please replace “CONR<sup>H</sup>R<sup>12</sup>” with –CONR<sup>11</sup>R<sup>12</sup>–; and at column 11, Table A, below row R<sup>16</sup>, please replace “R<sup>15</sup>” with –R<sup>16</sup>–.

**IN THE CLAIMS:**

Please replace Claims 12, 13, 14, and 15 with the following Claims:

12. A compound of the formula:



wherein:

R<sup>1</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, and CONR<sup>11</sup>R<sup>12</sup>;

R<sup>2</sup> and R<sup>3</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> haloalkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;

R<sup>4</sup> through R<sup>7</sup> each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR<sup>11</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> heteroalkyl; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methyldene, mono-substituted methyldene, di-substituted methyldene and carbonyl;

R<sup>8</sup> through R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, CN, OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup>, SR<sup>11</sup>, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, allyl, C<sub>2</sub>-C<sub>8</sub> alkenyl and C<sub>2</sub>-C<sub>8</sub> alkynyl;

R<sup>11</sup> and R<sup>12</sup> each is independently selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl;

R<sup>13</sup> is hydrogen;

R<sup>14</sup> and R<sup>16</sup> taken together form a bond or “—O—” bridge;


R<sup>15</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>-C<sub>4</sub> alkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl[.];

R<sup>21</sup> is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

13. A compound of the formula:



wherein:

R<sup>1</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, and CONR<sup>11</sup>R<sup>12</sup>;

R<sup>2</sup> and R<sup>3</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> haloalkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;

R<sup>4</sup> through R<sup>7</sup> each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR<sup>11</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> heteroalkyl; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R<sup>8</sup> through R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, CN, OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup>, SR<sup>11</sup>, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, allyl, C<sub>2</sub>-C<sub>8</sub> alkenyl and C<sub>2</sub>-C<sub>8</sub> alkynyl;

R<sup>11</sup> and R<sup>12</sup> each is independently selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl;

R<sup>13</sup> is hydrogen;

R<sup>14</sup>, R<sup>15</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>-C<sub>4</sub> alkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl[. . .];

R<sup>16</sup> and R<sup>17</sup> taken together are selected from the group of methylidene, mono-substituted methylidene, and di-substituted methylidene;


R<sup>21</sup> is hydrogen; or

R<sup>21</sup> and R<sup>20</sup> taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

14. A compound of the formula:



wherein:

R<sup>1</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, and CONR<sup>11</sup>R<sup>12</sup>;

R<sup>2</sup> and R<sup>3</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>–C<sub>6</sub> alkyl, and C<sub>1</sub>–C<sub>6</sub> haloalkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;

R<sup>4</sup> through R<sup>7</sup> each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR<sup>11</sup>, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> haloalkyl, and C<sub>1</sub>–C<sub>4</sub> heteroalkyl; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R<sup>8</sup> through R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, CN, OR<sup>11</sup>R<sup>12</sup>, SR<sup>11</sup>, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>–C<sub>8</sub> alkyl, C<sub>1</sub>–C<sub>8</sub> heteroalkyl, C<sub>1</sub>–C<sub>8</sub> haloalkyl, allyl, C<sub>2</sub>–C<sub>8</sub> alkenyl and C<sub>2</sub>–C<sub>8</sub> alkynyl;

R<sup>11</sup> and R<sup>12</sup> each is independently selected from the group of hydrogen, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> heteroalkyl, and C<sub>1</sub>–C<sub>4</sub> haloalkyl;

R<sup>13</sup> is hydrogen;

~~R<sup>14</sup>, R<sup>15</sup>, R<sup>17</sup>, R<sup>20</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>–C<sub>4</sub> alkyl, and C<sub>1</sub>–C<sub>4</sub> haloalkyl; R<sup>16</sup> and R<sup>18</sup> taken together form a bond when n is 1;~~

R<sup>14</sup>, R<sup>15</sup>, R<sup>17</sup>, R<sup>20</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>–C<sub>4</sub> alkyl, and C<sub>1</sub>–C<sub>4</sub> haloalkyl;

R<sup>16</sup> and R<sup>18</sup> taken together form a bond when n is 1;

R<sup>16</sup> and R<sup>19</sup> taken together form a bond when n is 0;

R<sup>21</sup> is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

Applicant : Lin Zhi et al.  
Patent No. : 7,071,205  
Issued : July 4, 2006  
Serial No. : 10/684,229  
Filed : October 10, 2003  
Page : 6 of 12

Attorney's Docket No.: 18202-020001 / 1088

15. A compound selected from the group of:

- ( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 24);  
( $\pm$ )-(5*l*,1'*u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 25);  
(+)-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 27);  
(-)-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 28);  
( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 29);  
( $\pm$ )-(5*l*,1'*u*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 30);  
(+)-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 32);  
(-)-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 33);  
( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 34);  
( $\pm$ )-(5*l*,1'*u*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 35);  
(+)-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 37);  
(-)-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 38);  
( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 39);

Applicant : Lin Zhi et al.  
Patent No. : 7,071,205  
Issued : July 4, 2006  
Serial No. : 10/684,229  
Filed : October 10, 2003  
Page : 7 of 12

Attorney's Docket No.: 18202-020001 / 1088

( $\pm$ )-(5*l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 41);  
( $\pm$ )-(5*l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 42);  
( $\pm$ )-(5*l,1'l*)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 44);  
( $\pm$ )-(5*l,1'u*)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 45);  
( $\pm$ )-(5*l,1'l*)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 47);  
( $\pm$ )-(5*l,1'u*)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 48);  
( $\pm$ )-(5*l,1'l*)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 50);  
( $\pm$ )-(5*l,1'u*)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 51);  
( $\pm$ )-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 52);  
( $\pm$ )-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 53);  
( $\pm$ )-(5*l,1'l*)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 55);  
( $\pm$ )-(5*l,1'u*)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 56);  
( $\pm$ )-(5*l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 58);  
( $\pm$ )-(5*l,1'u*)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 59);

Applicant : Lin Zhi et al.  
Patent No. : 7,071,205  
Issued : July 4, 2006  
Serial No. : 10/684,229  
Filed : October 10, 2003  
Page : 8 of 12

Attorney's Docket No.: 18202-020001 / 1088

( $\pm$ )-(5*l*,1'*l*)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 61);  
( $\pm$ )-(5*l*,1'*l*)-5-(3-ethylidene cyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 62);  
( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 63);  
( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 64);  
( $\pm$ )-(5*l*,1'*u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 65);  
( $\pm$ )-(5*l*,1'*l*)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 67);  
( $\pm$ )-(5*l*,1'*u*)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 68);  
( $\pm$ )-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 69);  
( $\pm$ )-(5*l*,1'*l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 71);  
(+)-(5*l*,1'*l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 73);  
(-)-(5*l*,1'*l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 74);  
( $\pm$ )-(5*l*,1'*l*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 75);  
( $\pm$ )-(5*l*,1'*u*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 76);  
( $\pm$ )-(5*l*,1'*l*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5H-chromeno[3,4-f]quinoline (compound 77);

Applicant : Lin Zhi et al.  
Patent No. : 7,071,205  
Issued : July 4, 2006  
Serial No. : 10/684,229  
Filed : October 10, 2003  
Page : 9 of 12

Attorney's Docket No.: 18202-020001 / 1088

( $\pm$ )-(5*l*,1'*l*)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 79);  
( $\pm$ )-(5*l*,1'*u*)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 80);  
( $\pm$ )-(5*l*,1'*l*)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 81);  
( $\pm$ )-(5*l*,1'*u*)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 82);  
( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5H-chromeno[3,4-f]quinoline (compound 83);  
( $\pm$ )-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 84);  
( $\pm$ )-(5*l*,1'*l*)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 85);  
( $\pm$ )-5-(3-methylidene-cyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 87);  
( $\pm$ )-(5*l*,1'*u*)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 88);  
( $\pm$ )-(5*l*,1'*l*)-5-(2-cycloheptenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 89);  
( $\pm$ )-(5*l*,1'*l*)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 91);  
( $\pm$ )-(5*l*,1'*u*)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 92);  
( $\pm$ )-(5*l*,1'*l*)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 94);  
( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylene-5H-chromeno[3,4-f]quinolin-3-ol (Compound 95);

Applicant : Lin Zhi et al.  
Patent No. : 7,071,205  
Issued : July 4, 2006  
Serial No. : 10/684,229  
Filed : October 10, 2003  
Page : 10 of 12

Attorney's Docket No.: 18202-020001 / 1088

( $\pm$ )-(5*l*,1'*l*)-5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 96);  
( $\pm$ )-(5*l*,1'*u*)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 97); and  
( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5H-chromeno[3,4-f]quinolin-4-one (Compound 98).

Applicant : Lin Zhi et al.  
Patent No. : 7,071,205  
Issued : July 4, 2006  
Serial No. : 10/684,229  
Filed : October 10, 2003  
Page : 11 of 12

Attorney's Docket No.: 18202-020001 / 1088

## REMARKS

A Certificate of Correction (Form PTO-1050) incorporating the above changes is included with this Request. Since not all the errors are those of the Patent Office, a check for \$100 is enclosed to cover the required fee. If it is determined that the fee amount is incorrect or if the check is missing, the Office is hereby authorized to charge the fee to Deposit Account No. 06-1050.

This Certificate of Correction seeks to correct errors and omissions by the PTO in the "U.S. PATENT DOCUMENTS" section of the References Cited, Item [56]. U.S. Patent number 6,001,846 is added, a copy of the examiner initialed PTO-1449 form delivered on July 1, 2005 is attached herewith as evidence for the incorporation of this reference. Additionally, correction of author names is requested for U.S. Patent numbers 6,566,358 and 6,566,372.

This Certificate of Correction seeks to correct an obvious spelling error by the PTO in the "OTHER PUBLICATIONS" section of the References Cited, Item [56].

This Certificate of Correction seeks to correct typographical errors introduced by the PTO in the Specification. The correction in column 8 to Table A, row R<sup>1</sup> seeks to correct list item "C<sub>1</sub>-C<sub>4</sub> haloalkyl" by inserting a subscript four (4) into "C<sub>1</sub>-C haloalkyl" as found in the originally filed application on page 15, row 1, column 1 of Table A. The correction in column 9 to Table A, row R<sup>9</sup> seeks to replace list item "CONR<sup>H</sup>R<sup>12</sup>" with "CONR<sup>11</sup>R<sup>12</sup>" as found in the originally filed application on page 17, row 2, column 1 of Table A. The correction in column 11 to Table A, row R<sup>16</sup> seeks to replace list item "R<sup>15</sup>" with "R<sup>16</sup>" as found in the originally filed application on page 19, row 2, column 1 of Table A.

This Certificate of Correction seeks to correct errors in the Claims. Claim 12 is amended to correct the punctuation error at column 41, line 6 by replacing the period with a semicolon. Claim 13 is amended to correct the punctuation error at column 41, line 59 by replacing the period with a semicolon. Claim 14 is amended to correct the punctuation error at column 42, line 46 by inserting a semicolon between "haloalkyl" and "R<sup>16</sup>". Claim 15 is amended to correct the error introduced by the PTO in compound 55 by inserting a comma after "51" and by


Applicant : Lin Zhi et al.  
Patent No. : 7,071,205  
Issued : July 4, 2006  
Serial No. : 10/684,229  
Filed : October 10, 2003  
Page : 12 of 12

Attorney's Docket No.: 18202-020001 / 1088

inserting the letter "l" following "1" as found on page 79, line 1 of the originally filed application.

Accordingly, none of the requested changes constitute new matter. Patentee respectfully requests correction of errors by issuance of a Certificate of Correction.

Respectfully submitted,

  
Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 18202-020001 / 1088

**Address all correspondence to:**

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-4777  
Facsimile: (202) 626-7796  
email: seidman@fr.com

10656908.doc

Staple  
Here  
Only

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT No. : 7,071,205  
DATED : JULY 4, 2006  
INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

### IN THE TITLE PAGES:

In Item [56] References Cited, in U.S. PATENT DOCUMENTS:  
please add the following reference: -6,001,846 A 12/1999 Edwards et al. 514/285–  
in 6,566,358 please replace “Zhi et al.” with –Zhang et al.–  
in 6,566,372 please replace “West et al.” with –Zhi et al.–

In Item [56] References Cited, in OTHER PUBLICATIONS:  
in Hamann et al., please replace “dihyrd” with –dihydro–

### IN THE SPECIFICATION:

At column 8, Table A, row R<sup>1</sup>, please replace “C<sub>1</sub>-C haloalkyl” with –C<sub>1</sub>-C<sub>4</sub> haloalkyl–  
at column 9, Table A, row R<sup>9</sup>, please replace “CONR<sup>H</sup>R<sup>12</sup>,” with –CONR<sup>11</sup>R<sup>12</sup>–  
at column 11, Table A, below row R<sup>16</sup>, please replace “R<sup>15</sup>” with –R<sup>16</sup>–

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130

SEP 13 2006

Staple  
Here  
Only

**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**


PATENT No. : 7,071,205  
 DATED : JULY 4, 2006  
 INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**IN THE CLAIMS:**

Please replace Claims 12, 13, 14, and 15 with the following Claims:

12. A compound of the formula:



wherein:

R<sup>1</sup> is selected from the group of hydrogen, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> haloalkyl, C<sub>1</sub>–C<sub>4</sub> heteroalkyl, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, and CONR<sup>11</sup>R<sup>12</sup>;

R<sup>2</sup> and R<sup>3</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>–C<sub>6</sub> alkyl, and C<sub>1</sub>–C<sub>6</sub> haloalkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;

R<sup>4</sup> through R<sup>7</sup> each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR<sup>11</sup>, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> haloalkyl, and C<sub>1</sub>–C<sub>4</sub> heteroalkyl; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methyldene, mono-substituted methyldene, di-substituted methyldene and carbonyl;

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
 Fish & Richardson P.C.  
 12390 El Camino Real  
 San Diego, California 92130

SEARCHED INDEXED  
 SERIALIZED FILED

Staple  
Here  
Only


**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205  
 DATED : JULY 4, 2006  
 INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R<sup>8</sup> through R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, CN, OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup>, SR<sup>11</sup>, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, allyl, C<sub>2</sub>-C<sub>8</sub> alkenyl and C<sub>2</sub>-C<sub>8</sub> alkynyl;  
 R<sup>11</sup> and R<sup>12</sup> each is independently selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl;  
 R<sup>13</sup> is hydrogen;  
 R<sup>14</sup> and R<sup>16</sup> taken together form a bond or “—O—” bridge;  
 R<sup>15</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>-C<sub>4</sub> alkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl;  
 R<sup>21</sup> is hydrogen; and  
 n is 0, 1, 2, or 3;  
 or a pharmaceutically acceptable salt thereof.

13. A compound of the formula:



(I)

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
 Fish & Richardson P.C.  
 12390 El Camino Real  
 San Diego, California 92130

SEP 18 2006

Staple  
Here  
Only

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205  
DATED : JULY 4, 2006  
INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

wherein:

R<sup>1</sup> is selected from the group of hydrogen, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> haloalkyl, C<sub>1</sub>–C<sub>4</sub> heteroalkyl, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, and CONR<sup>11</sup>R<sup>12</sup>;  
R<sup>2</sup> and R<sup>3</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>–C<sub>6</sub> alkyl, and C<sub>1</sub>–C<sub>6</sub> haloalkyl; or  
R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;  
R<sup>4</sup> through R<sup>7</sup> each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR<sup>11</sup>, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> haloalkyl, and C<sub>1</sub>–C<sub>4</sub> heteroalkyl; or  
R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or  
R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methyldene, mono-substituted methyldene, di-substituted methyldene and carbonyl;  
R<sup>8</sup> through R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, CN, OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup>, SR<sup>11</sup>, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>–C<sub>8</sub> alkyl, C<sub>1</sub>–C<sub>8</sub> heteroalkyl, C<sub>1</sub>–C<sub>8</sub> haloalkyl, allyl, C<sub>2</sub>–C<sub>8</sub> alkenyl and C<sub>2</sub>–C<sub>8</sub> alkynyl;  
R<sup>11</sup> and R<sup>12</sup> each is independently selected from the group of hydrogen, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> heteroalkyl, and C<sub>1</sub>–C<sub>4</sub> haloalkyl;  
R<sup>13</sup> is hydrogen;  
R<sup>14</sup>, R<sup>15</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>–C<sub>4</sub> alkyl, and C<sub>1</sub>–C<sub>4</sub> haloalkyl;  
R<sup>16</sup> and R<sup>17</sup> taken together are selected from the group of methyldene, mono-substituted methyldene, and di-substituted methyldene;  
R<sup>21</sup> is hydrogen; or  
R<sup>21</sup> and R<sup>20</sup> taken together form a bond;  
n is 0, 1, 2, or 3;  
or a pharmaceutically acceptable salt thereof.

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130

Ser 13 400


Staple  
Here  
Only

**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205  
 DATED : JULY 4, 2006  
 INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

14. A compound of the formula:



wherein:

R<sup>1</sup> is selected from the group of hydrogen, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> haloalkyl, C<sub>1</sub>–C<sub>4</sub> heteroalkyl, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, and CONR<sup>11</sup>R<sup>12</sup>;

R<sup>2</sup> and R<sup>3</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>–C<sub>6</sub> alkyl, and C<sub>1</sub>–C<sub>6</sub> haloalkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;

R<sup>4</sup> through R<sup>7</sup> each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR<sup>11</sup>, C<sub>1</sub>–C<sub>4</sub> alkyl, C<sub>1</sub>–C<sub>4</sub> haloalkyl, and C<sub>1</sub>–C<sub>4</sub> heteroalkyl; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methyldene, mono-substituted methyldene, di-substituted methyldene and carbonyl;

R<sup>8</sup> through R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, CN, OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup>, SR<sup>11</sup>, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>–C<sub>8</sub> alkyl, C<sub>1</sub>–C<sub>8</sub> heteroalkyl, C<sub>1</sub>–C<sub>8</sub> haloalkyl, allyl, C<sub>2</sub>–C<sub>8</sub> alkenyl and C<sub>2</sub>–C<sub>8</sub> alkynyl;

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
 Fish & Richardson P.C.  
 12390 El Camino Real  
 San Diego, California 92130

SEP 13 2005

Staple  
Here  
Only

**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205  
DATED : JULY 4, 2006  
INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R<sup>11</sup> and R<sup>12</sup> each is independently selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl;  
R<sup>13</sup> is hydrogen;  
R<sup>14</sup>, R<sup>15</sup>, R<sup>17</sup>, R<sup>20</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>-C<sub>4</sub> alkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl;  
R<sup>16</sup> and R<sup>18</sup> taken together form a bond when n is 1;  
R<sup>16</sup> and R<sup>19</sup> taken together form a bond when n is 0;  
R<sup>21</sup> is hydrogen; and  
n is 0, 1, 2, or 3;  
or a pharmaceutically acceptable salt thereof.

15. A compound selected from the group of:

(±)-(5l,1'l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 24);  
(±)-(5l,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 25);  
(+)-(5l,1'l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 27);  
(-)-(5l,1'l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 28);  
(±)-(5l,1'l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 29);

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130

SER 13 4000

Staple  
Here  
Only

**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205  
DATED : JULY 4, 2006  
INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(5*l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 30);  
(+)-(5*l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 32);  
(-)-(5*l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 33);  
(±)-(5*l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 34);  
(±)-(5*l,1'u*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 35);  
(+)-(5*l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 37);  
(-)-(5*l,1'l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 38);  
(±)-(5*l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 39);  
(±)-(5*l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 41);  
(±)-(5*l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 42);  
(±)-(5*l,1'l*)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 44);  
(±)-(5*l,1'u*)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 45);

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130

SEARCHED INDEXED  
SERIALIZED FILED

Staple  
Here  
Only**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205  
DATED : JULY 4, 2006  
INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(5l,1'l)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 47);  
(±)-(5l,1'u)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 48);  
(±)-(5l,1'l)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 50);  
(±)-(5l,1'u)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 51);  
(±)-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 52);  
(±)-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 53);  
(±)-(5l,1'l)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 55);  
(±)-(5l,1'u)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 56);  
(±)-(5l,1'l)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 58);  
(±)-(5l,1'u)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 59);  
(±)-(5l,1'l)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 61);  
(±)-(5l,1'l)-5-(3-ethylidene cyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 62);

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130

SEP 13 2006

Staple  
Here  
Only

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205  
DATED : JULY 4, 2006  
INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(5*l,1'l*)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 63);  
(±)-(5*l,1'l*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 64);  
(±)-(5*l,1'u*)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 65);  
(±)-(5*l,1'l*)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 67);  
(±)-(5*l,1'u*)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 68);  
(±)-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 69);  
(±)-(5*l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 71);  
(+)-(5*l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 73);  
(-)-(5*l,1'l*)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 74);  
(±)-(5*l,1'l*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 75);  
(±)-(5*l,1'u*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 76);  
(±)-(5*l,1'l*)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5H-chromeno[3,4-f]quinoline (compound 77);

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130

SCT 13 6000

Staple  
Here  
Only

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT No. : 7,071,205  
DATED : JULY 4, 2006  
INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(51,1'l)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 79);  
(±)-(51,1'u)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 80);  
(±)-(51,1'l)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 81);  
(±)-(51,1'u)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 82);  
(±)-(51,1'l)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5H-chromeno[3,4-f]quinoline (compound 83);  
(±)-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]-quinoline (compound 84);  
(±)-(51,1'l)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 85);  
(±)-5-(3-methylidene-cyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 87);  
(±)-(51,1'u)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 88);  
(±)-(51,1'l)-5-(2-cycloheptenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 89);  
(±)-(51,1'l)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 91);  
(±)-(51,1'u)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 92);

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130

Sep 13 2006

Staple  
Here  
Only**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205  
DATED : JULY 4, 2006  
INVENTOR(S) : LIN ZHI, ET AL.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

( $\pm$ )-(5*l*,1'*l*)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 94);  
( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylene-5H-chromeno[3,4-f]quinolin-3-ol (Compound 95);  
( $\pm$ )-(5*l*,1'*l*)-5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 96);  
( $\pm$ )-(5*l*,1'*u*)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 97); and  
( $\pm$ )-(5*l*,1'*l*)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5H-chromeno[3,4-f]quinolin-4-one (Compound 98).

MAILING ADDRESS OF SENDER:

PATENT NO. 7,071,205

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130

SEP 13 2006



Sheet 1 of 5

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-020001/1088	Application No. 10/684,229
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))		Applicant Lin Zhi et al.		
		Filing Date October 10, 2003	Group Art Unit 1625	

#### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
CA	AA	20030216388	11/20/03	Zhang et al.	514	230.5	03/12/03
CA	AB	20030220388	11/27/03	Fensome et al.	514	414	06/06/03
CA	AC	20030225109	12/04/03	Fensome et al.	514	256	04/22/03
CA	AD	2004/0147530	10/10/03	Zhi et al.	514	256	10/10/03
CA	AE	20040152717	08/05/04	Zhi et al.	514	285	10/10/03
CA	AF	20040186101	09/23/04	Zhang et al.	514	230.5	01/29/04
CA	AG	5,506,102	04/09/96	McDonnell et al.	435	6	10/28/93
CA	AH	5,688,808	11/18/97	Jones et al.	514	285	06/05/95
CA	AI	5,688,810	11/18/97	Jones et al.	514	311	06/05/95
CA	AJ	5,696,130	12/09/97	Jones et al.	514	291	06/05/95
CA	AK	5,696,133	12/09/97	Jones et al.	514	314	06/05/95
CA	AL	5,808,139	09/15/98	Pathirana et al.	560	138	09/08/94
CA	AM	5,994,544	11/30/99	Jones et al.	546	62	10/08/97
CA	AN	6,001,846	07/25/00	Bender et al.	514	285	02/17/98
CA	AO	6,093,821	07/25/00	Jones et al.	544	333	10/08/97
CA	AP	6,093,825	07/25/00	Jones et al.	546	62	05/27/98
CA	AQ	6,093,826	07/25/00	Edwards et al.	546	62	06/08/98
CA	AR	6,121,450	09/19/00	Jones et al.	546	81	10/08/97
CA	AS	6,172,241	01/09/01	Edwards et al.	549	280	10/15/99
CA	AT	6,268,497	07/31/01	Edwards et al.	546	62	04/12/00
CA	AU	6,306,851	10/23/01	Santilli et al.	514	230.5	04/19/00
CA	AV	6,319,912	10/20/01	Grubb et al.	514	171	04/19/00
CA	AW	6,329,416	12/11/01	Grubb et al.	514	415	04/19/00
CA	AX	6,339,098	01/15/02	Collins et al.	514	373	04/19/00
CA	AY	6,355,648	03/12/02	Fensome et al.	514	275	04/19/00
CA	AZ	6,358,947	03/19/02	Zhi et al.	514	229.5	04/19/00
CA	BA	6,358,948	03/19/02	Zhang et al.	514	230.5	04/19/00

Examiner Signature	Date Considered
Ali Vach	12/14/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SEPT 13 2006